Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial.
Kate Leslie, Jai N Darvall, Matthew T V Chan et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 4, multicenter, randomized controlled trial evaluated the effects of sugammadex versus neostigmine on postoperative pulmonary complications in adults undergoing abdominal or thoracic surgery. Among 3498 patients, those receiving sugammadex experienced a lower incidence of complications or death (19.0% vs 21.5%, risk ratio 0.88, p=0.049), suggesting a potential benefit of sugammadex in this context.
Key findings
- Postoperative pulmonary complications or death occurred in 19.0% of the sugammadex group versus 21.5% in the neostigmine group.
- Atelectasis was reported in 18.4% of patients receiving sugammadex compared to 21.1% receiving neostigmine.
- Death occurred in 0.1% of patients in both groups, indicating no significant difference.
Why it matters
The findings suggest that sugammadex may reduce the risk of postoperative pulmonary complications compared to neostigmine, which is important for improving patient outcomes following surgery. Understanding the implications of neuromuscular blockade reversal can enhance postoperative care strategies.